Aviragen Therapeutics Competitors and Similar CompaniesClear all

Aviragen Therapeutics's competitors and similar companies include Genentech, UCB and Cipla.

	Aviragen Therapeutics Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 1969	Founding Date 1976	Founding Date 1928	Founding Date 1935
Type	Type Public	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Alpharetta, US HQ	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 21	Employees 18,077	Employees 9,052	Employees 27,764
Valuation ($)	Valuation ($) 705.2 m	Valuation ($) N/A	Valuation ($) 34.3 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods ₹97.2b (FY, 2026)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit ₹184.4b (FY, 2026)
Net income	Net income N/A	Net income N/A	Net income €1.6b (FY, 2025)	Net income ₹38.7b (FY, 2026)